Young Richard A 4
4 · Syros Pharmaceuticals, Inc. · Filed Jun 2, 2023
Insider Transaction Report
Form 4
Young Richard A
Director
Transactions
- Award
Common Stock
2023-06-01+4,000→ 36,171 total - Award
Stock Option (right to buy)
2023-06-01+6,000→ 6,000 totalExercise: $3.70Exp: 2033-05-31→ Common Stock (6,000 underlying)
Footnotes (2)
- [F1]The amount of securities beneficially owned following the transaction reported in this Form 4 reflects the 1-for-10 reverse stock split effected by the issuer on September 16, 2022.
- [F2]The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments of 8.33% of the shares underlying the award until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date.